Much emphasis has been placed on cardiovascular benefits associated with particular diabetes medications. Until now, data supporting renal benefits of specific diabetes medications has been absent. CREDENCE trial which enrolled persons with diabetes and chronic kidney disease produced results revealing positive renal benefits of canagliflozin. Persons enrolled in the study were on a stable dose of medication blocking renin-angiotensin system. Positive results were also found in terms of cardiovascular outcomes. Interestingly no increased risk of amputation with canagliflozin was found in this study. Potential for novel renal indication can be anticipated for canagliflozin in the future. To learn more about this game changing study, please click below.
https://www.nejm.org/doi/full/10.1056/NEJMoa1811744
Please share your thoughts and subscribe to receive my blogs.
#canagliflozin #renal #cardiovascular #benefits
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.